MediBeacon Inc.

MediBeacon Inc. is a medical technology company based in St. Louis, specializing in fluorescent tracer agents and transdermal measurement systems. Founded in 2012, the company focuses on real-time monitoring of organ function, particularly kidney function. MediBeacon utilizes a proprietary pyrazine-based fluorescent tracer platform combined with transdermal detection technology to noninvasively measure physiological functions, such as glomerular filtration rate (GFR), which is essential for assessing kidney health. The company's core product includes proprietary fluorescent tracer agents, notably relmapirazin, and a transdermal sensor system that allows for continuous monitoring without invasive procedures. MediBeacon holds over 47 U.S. patents and more than 170 patents globally, covering its technology and applications across various medical fields. The company is advancing its clinical studies and has submitted premarket approval modules to the FDA for its GFR measurement system. MediBeacon targets academic medical centers, research institutions, and healthcare providers, aiming to enhance patient outcomes through precise organ function data.

• Employees 25
• Founded 2012
• Annual Revenue $9312000
• Total Funding $135759784